Redeye returns with an update on AlzeCure following the landmark USD2.2bn QuantumCell agreement for the NeuroRestore platform - a massive milestone arriving hot on the heels of the company’s USD1bn Eli Lilly partnership. This dual validation by top-tier players provides definitive credibility to AlzeCure’s platform potential while lifting its cash position to roughly a quarter of a billion SEK. By incorporating the transaction terms into our model, lowering the WACC, and removing the previously assumed rights issue, we arrive at a new base case of SEK 14.3 (8.8). We conclude this update with a concise recap of the NeuroRestore platform and its lead asset, ACD856.
LÄS MER
